Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 4/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | SRC | P12931 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1324598 | 0.88 | LCK (0.38) | LCKIDO1TDO2GRIN2BCYP11B2 | |
| SCHEMBL1324582 | 0.76 | CYP11B1 (0.37) | LCKIDO1TDO2GRIN2BCYP11B2 | |
| SCHEMBL1325748 | 0.75 | DCLRE1B (0.41) | LCKIDO1TDO2SRC | |
| SCHEMBL18817331 | 0.73 | LCK (0.38) | LCKSRCBRD9 | |
| SCHEMBL1325329 | 0.73 | RPS6KB1 (0.43) | LCKGRIN2BBRD9 | |
| SCHEMBL18817126 | 0.71 | MAOA (0.36) | LCKCYP11B2SRCCYP11B1BRD9 | |
| SCHEMBL18817292 | 0.70 | DHFR (0.34) | GRIN2BPGRPTGS2 | |
| SCHEMBL1325392 | 0.69 | GRIA1 (0.36) | PTGS2 | |
| SCHEMBL16038490 | 0.68 | PDE4B (0.35) | IDO1TDO2CYP11B2CYP11B1 | |
| SCHEMBL18817209 | 0.68 | PTGS2 (0.36) | GRIN2BPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193721-B2 | Fused derivatives as PI3Kδ inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193721-B2 | Fused derivatives as PI3Kδ inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193721-B2 | Fused derivatives as PI3Kδ inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2015-11-24 | — | — | US | disclosed |
| EP-2558463-A1 | FUSED DERIVATIVES AS I3 INHIBITORS | Incyte Corporation (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20110281884-A1 | FUSED DERIVATIVES AS PI3KDELTA INHIBITORS | INCYTE CORPORATION | 2011-11-17 | — | — | US | disclosed |
| US-20110281884-A1 | FUSED DERIVATIVES AS PI3KDELTA INHIBITORS | INCYTE CORPORATION | 2011-11-17 | — | — | US | disclosed |
| WO-2011130342-A1 | FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS | INCYTE CORPORATION (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011130342-A1 | FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS | INCYTE CORPORATION (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281884-A1 | FUSED DERIVATIVES AS PI3KDELTA INHIBITORS | PIK3CD, PIK3CA, PIK3CB | LCK 215/4885IDO1 2480/4885TDO2 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.